Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

Scientists find new way to kill liver cancer cells

Scientists find new way to kill liver cancer cells

New organ-on-a-chip technology provides simple setting to study blood vessel formation

New organ-on-a-chip technology provides simple setting to study blood vessel formation

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Reduced dose of chemotherapy has no effect on overall survival of liver cancer patients

Reduced dose of chemotherapy has no effect on overall survival of liver cancer patients

Stivarga receives expanded FDA approval for treatment of liver cancer

Stivarga receives expanded FDA approval for treatment of liver cancer

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Study provides insight into how microRNA may amplify effects of drug treatment in liver cancer

Study provides insight into how microRNA may amplify effects of drug treatment in liver cancer

New computational tool can predict personal cancer driver genes to optimize treatment

New computational tool can predict personal cancer driver genes to optimize treatment

Scientists unravel novel role of signalling protein in common type of liver cancer

Scientists unravel novel role of signalling protein in common type of liver cancer

Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Research could help clinicians identify patients who may benefit from targeted therapy for liver cancer

Research could help clinicians identify patients who may benefit from targeted therapy for liver cancer

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.